ストックスクリーナーアプリを入手
44.99
1.08%
0.48
アフターアワーズ：
44.91
-0.08
-0.18%
Alkermes Plc (ALKS) 最新ニュース
Alkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS) - Seeking Alpha
Did Positive Vibrance-2 Data for Alixorexton Just Shift Alkermes' (ALKS) Investment Narrative? - simplywall.st
Alkermes stock hits 52-week high at 45.76 USD By Investing.com - Investing.com India
Alkermes presents detailed positive results from Vibrance-2 phase 2 study of Alixorexton in adults with narcolepsy type 2 at SLEEP 2026 - MSN
Alkermes stock hits 52-week high at 45.76 USD - Investing.com
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Alkermes (ALKS) Study Results Highlight Potential Benefits for N - GuruFocus
Needham raises Alkermes stock price target on narcolepsy drug data By Investing.com - Investing.com Nigeria
Needham raises Alkermes stock price target on narcolepsy drug data - Investing.com
H.C. Wainwright reiterates Alkermes stock rating on trial data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Alkermes stock rating on trial data - Investing.com
ALKS Maintains Buy Rating by Needham -- Price Target Raised to $54.00 - GuruFocus
Alkermes Plc (ALKS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alkermes Plc (ALKS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alkermes Plc (ALKS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alkermes Plc (ALKS) Institutional Confidence - TradingKey
Alkermes Plc (ALKS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout
Alkermes (ALKS) Shares Fall 31% Despite Positive Phase 2 Trial R - GuruFocus
Alkermes (ALKS) Advances Narcolepsy Treatment with Positive Phas - GuruFocus
Alkermes reports positive phase 2 results for narcolepsy drug By Investing.com - Investing.com India
Alkermes plummets on mid-stage Alixorexton data for narcolepsy - MSN
Alkermes Plc (ALKS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alkermes Plc (ALKS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alkermes reports positive phase 2 results for narcolepsy drug - Investing.com
Alkermes Plc (ALKS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alkermes stock jumps as narcolepsy drug hits trial goals - Investing.com
Alkermes stock jumps as narcolepsy drug hits trial goals By Investing.com - Investing.com UK
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 - The Daily Tribune News
REGBlackRock GroupSAR 6- ALKERMES PLC - TradingView
Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe - Sleep Review
Alkermes plc Stock (IE00B56GVS15): Orphan-Drug Boost For Sleep Disorder Candidate Alixorexton - AD HOC NEWS
Alkermes receives transatlantic orphan drug designations for alixorexton - grafa.com
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe - BioSpace
Alkermes’ alixorexton receives orphan drug designations in US, EU By Investing.com - Investing.com Australia
Alkermes’ alixorexton receives orphan drug designations in US, EU - Investing.com
Alkermes (ALKS) wins orphan drug designations in U.S. and Europe for alixorexton - Stock Titan
New narcolepsy drug wins rare-disease backing in U.S., Europe - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: Growth Potential With A 28.20% Revenue Surge - DirectorsTalk Interviews
Why (ALKS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Sell: Christopher Wright Sells 2,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes (ALKS) director sells 2,000 shares under Rule 10b5-1 plan - Stock Titan
Alkermes plc (ALKS) Rule 144 notice: 2,000 vested RSU shares listed - Stock Titan
Alkermes' alixorexton gains FDA orphan drug status for idiopathic hypersomnia - MSN
Alkermes (ALKS) Receives FDA Orphan Designation for Alixorexton - GuruFocus
Alkermes (ALKS) Receives Orphan Drug Designation for Alixorexton - GuruFocus
Alkermes touts orexin ambitions as Alixorexton enters phase 3 and CEO transition nears - MSN
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears - Yahoo Finance
ALKS: Orexin agonist program advances with strong clinical data, strategic acquisition, and leadership transition - TradingView
ALKS: Orexin agonist advances, Avadel integration, and pipeline expansion drive strategic momentum - TradingView
Alkermes stock hits 52-week high at 44.58 USD By Investing.com - Investing.com Australia
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tel - GuruFocus
Alkermes Jumps 5.6% After RBC Capital Maintains Outperform - AlphaStreet
Alkermes stock hits 52-week high at 44.58 USD - Investing.com
ALKS Maintained by RBC Capital -- Price Target Raised to $56.00 - GuruFocus
11.23%
0.45%
大文字化:
|
ボリューム (24 時間):